

Patient Card

For patients receiving treatment with ipilimumab only

This document has been approved by HSA as of 17-09-2025. Local Approval Number:731-SG-2500002



ull Bristol Myers Squibb

IMPORTANT Information for Patients

Carry this card with you at all times to inform healthcare professionals that you are receiving treatment with YERVOY (ipilimumab).



Ipilimumab is a medicine that helps to activate your immune system so that T-cells (a type of white blood cells) can fight cancer cells.



With ipilimumab, there is a risk that your activated immune system can harm healthy cells in your body, which may cause potentially serious or even life-threatening side effects. These side effects may affect different parts of the body.



Parts of your body

If you have any signs or symptoms, tell your doctor right away. This includes any other possible side effects not included in this card.

Possible signs and symptoms

SIGNS AND SYMPTOMS TO LOOK OUT FOR

	Bowel and stomach	Diarrhoea (watery, loose, or soft stools), bloody or dark-coloured stools, more frequent bowel movements than usual, pain or tenderness in your stomach or abdomen area, nausea or vomiting
	Eye	Redness in the eye, pain in the eye, vision problems, or blurry vision
	Hormone glands	Rapid heartbeat, increased sweating, weight gain or loss, feeling cold, hair loss, constipation, deeper voice, fever, tiredness, headache, dizziness or fainting, feeling more hungry or thirsty than usual, needing to urinate more often, or behavioural changes (eg, less sex drive, being irritable or forgetful)
#	Liver	Eye or skin yellowing (jaundice), pain on the right side of your stomach area, dark urine, or bleeding
	Lungs	Shortness of breath, cough, or chest pain
	Heart	Shortness of breath, irregular heartbeat, feeling tired, or chest pain
*	Nerves	Muscle weakness, numbness or tingling in legs, arms, or face, dizziness, loss of consciousness or difficulty waking up
	Skin	Skin rash with or without itching, dry skin, blisters and/or peeling of the skin, mouth sores, swelling of the face or lymph glands

Other important side effects:

Severe infusion reactions:

Reactions to infusing ipilimumab into the bloodstream might occur. Tell your doctor or nurse right away if you get these symptoms: chills or shaking, itching or rash, flushing, difficulty breathing, dizziness, fever, and feeling like passing out.

IMPORTANT

- Tell your doctor of any previous medical conditions.
- Early treatment of side effects reduces the likelihood that ipilimumab treatment will need to be temporarily or permanently stopped.
- Signs and symptoms that may appear mild can quickly worsen if left untreated.
- DO NOT try to treat these symptoms yourself.
- Signs and symptoms can appear during treatment or may be delayed and may occur weeks to months after your last ipilimumab injection.

For more information, please talk to your doctor.

IMPORTANT Information for Healthcare Professionals

- This patient is treated with ipilimumab monotherapy, which may increase the risk of immune-related adverse reactions, including but not limited to those listed on this card.
- Immune-related adverse reactions may appear at any time during treatment with ipilimumab or months after its discontinuation.
- Assess patients for signs and symptoms of immunerelated adverse reactions. Early diagnosis and appropriate management are essential to minimise life-threatening complications.
- Consultation with an oncologist or other medical specialist may be helpful for management of organ-specific immunerelated adverse reactions.
- Please refer to the YERVOY (ipilimumab) Singapore package insert or call Medical Information on 1800 415 5182 for more information.

The healthcare professional treating this patient with ipilimumab should complete the 'My Doctor's Contact Information' section of this Patient Card.

My Doctor's Contact Information (who prescribed ipilimumab)		
Name of Doctor:		
Office Phone:		
After-Hours Phone:		
My Contact Information		
My Name:		
My Phone Number:		
Emergency Contact (name and phone number):		